CLL-769: Efficacy and Safety of Zanubrutinib in a Fit Subgroup of Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL): Post Hoc Analyses From the SEQUOIA StudyMazyar Shadman, Talha Munir, Constantine S. Tam et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 1
An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLLMazyar Shadman, Talha Munir, Tian Tian et al.|Blood Advances|2026Cited by 1
SEQUOIA 5-YEAR FOLLOW-UP IN ARM C: FRONTLINE ZANUBRUTINIB MONOTHERAPY IN PATIENTS WITH DEL(17P) AND TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMARuddy Dalfeor, JR Brown, Jamie Hirata et al.|Hematology Transfusion and Cell Therapy|2025Cited by 0